{
    "Trade/Device Name(s)": [
        "CYFRA 21-1 EIA Kit",
        "CYFRA 21-1 EIA"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K100831",
    "Predicate Device Reference 510(k) Number(s)": [
        "K990774"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OVK"
    ],
    "Summary Letter Date": "May 18, 2011",
    "Summary Letter Received Date": "May 19, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Soluble cytokeratin 19 fragments",
        "CYFRA 21-1"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Microplate spectrophotometer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Solid phase non-competitive immunoassay"
    ],
    "Methodologies": [
        "Immunological assay"
    ],
    "Submission Type(s)": [
        "Kit",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for CYFRA 21-1 EIA Kit for quantitative determination of cytokeratin 19 fragments in human serum as an aid in monitoring lung cancer.",
    "Indications for Use Summary": "Quantitative determination of soluble cytokeratin 19 fragments in human serum to aid in monitoring disease progression during the course of disease and treatment in lung cancer patients.",
    "fda_folder": "Immunology"
}